Seeing is Believing: Wall Street's Slow Reaction to Rimonabant

An FDA advisory committee's recommendation against the approval of Sanofi-Aventis' rimonabant caught many investors off guard. It's hard to believe drug safety issues can still surprise Wall Street, but there are some reasons why analysts lacked clarity on rimonabant.